Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) has been assigned an average rating of “Reduce” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $65.00.
A number of analysts have issued reports on QNCX shares. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Maxim Group downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Citigroup downgraded Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 29th.
Read Our Latest Research Report on QNCX
Quince Therapeutics Stock Down 2.5%
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.71.
Institutional Trading of Quince Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of QNCX. Nantahala Capital Management LLC acquired a new stake in shares of Quince Therapeutics during the 2nd quarter worth about $4,172,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Quince Therapeutics during the 4th quarter worth about $7,538,000. Millennium Management LLC increased its position in shares of Quince Therapeutics by 1,152.9% during the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after purchasing an additional 1,276,094 shares during the last quarter. Superstring Capital Management LP acquired a new stake in shares of Quince Therapeutics during the 4th quarter worth about $2,877,000. Finally, ADAR1 Capital Management LLC increased its position in shares of Quince Therapeutics by 442.1% during the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock worth $1,263,000 after purchasing an additional 632,076 shares during the last quarter. 30.75% of the stock is owned by institutional investors and hedge funds.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
Featured Stories
- Five stocks we like better than Quince Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
